bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:BLUE
- CUSIP: N/A
- Web: www.bluebirdbio.com
Capitalization:- Market Cap: $3.27 billion
- Outstanding Shares: 40,950,000
Average Prices:- 50 Day Moving Avg: $86.31
- 200 Day Moving Avg: $76.75
- 52 Week Range: $36.62 - $100.40
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -10.98
- P/E Growth: 0.29
Sales & Book Value:- Annual Revenue: $11.49 million
- Price / Sales: 284.40
- Book Value: $19.92 per share
- Price / Book: 4.01
Profitability:- EBIDTA: ($250,640,000.00)
- Net Margins: -3,941.72%
- Return on Equity: -30.79%
- Return on Assets: -24.93%
Debt:- Current Ratio: 9.01%
- Quick Ratio: 9.01%
Misc:- Average Volume: 694,529 shs.
- Beta: 2.15
- Short Ratio: 8.8
Frequently Asked Questions for bluebird bio (NASDAQ:BLUE)
What is bluebird bio's stock symbol?
bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."
How were bluebird bio's earnings last quarter?
bluebird bio Inc (NASDAQ:BLUE) announced its earnings results on Wednesday, May, 3rd. The company reported ($1.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.76) by $0.08. The business had revenue of $6.83 million for the quarter, compared to analyst estimates of $1.51 million. bluebird bio had a negative net margin of 3,941.72% and a negative return on equity of 30.79%. View bluebird bio's Earnings History.
When will bluebird bio make its next earnings announcement?
Where is bluebird bio's stock going? Where will bluebird bio's stock price be in 2017?
16 brokers have issued 12 month price objectives for bluebird bio's stock. Their forecasts range from $37.00 to $135.00. On average, they expect bluebird bio's share price to reach $87.54 in the next twelve months. View Analyst Ratings for bluebird bio.
What are analysts saying about bluebird bio stock?
Here are some recent quotes from research analysts about bluebird bio stock:
- 1. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (5/8/2017)
- 2. Maxim Group analysts commented, "bluebird reported 1Q17 with revenue of $6.8M (collaboration revenue) and a net loss of $68.7M." (5/5/2017)
- 3. BTIG Research analysts commented, "Forecasts and Increased Conviction in Corp Strategy We have updated our outlook for bluebird bio (BLUE) and are raising our Price Target to $112 from $83 previously. Key points to our update include, 1) a positive outlook for the bb2121 update at ASCO, 2) favorable comps for LentiGlobin pricing, and 3) higher conviction in overall corporate strategy. We maintain our Buy recommendation. Positive Risk Skew for bb2121 Dataset at ASCO: We anticipate that investors are looking for a continuation of responses within the 15 x 10^7 dose cohort along with sCR’s within the higher dose cohort (45×10^7), as there will be +3mos follow-up available for a number of patients (actual number not disclosed). SAEs such as CRS and Neurotox will be a focus, although we think that the dosing will be able to continue to push higher given the limited toxicity recorded to date. Our model now includes specific estimates for bb2121 reaching ~$287m of sales by 2021, under the assumption of a fast-track approval process for 4 th line BCMA+ Multiple Myeloma." (5/1/2017)
- 4. BMO Capital Markets analysts commented, "We believe investors' focus will remain on continued progress of bluebird's pipeline where we look for multiple data readouts in 2017. For bb2121 we believe the focus will remain on safety, which we see as key point of differentiation versus other BCMA-focused CAR-T programs. For LentiGlobin we look for confirmation that Process 2 leads to better outcomes in SCD (data at ASH, December 9-12) and in ??0/??0 TDT. We have updated our model for 4Q results and reiterate our Market Perform rating and $83 price target." (2/23/2017)
Who are some of bluebird bio's key competitors?
Some companies that are related to bluebird bio include Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), Kite Pharma (KITE), BIO-TECHNE Corp (TECH), Galapagos NV (GLPG), Opko Health (OPK), Nektar Therapeutics (NKTR), ACADIA Pharmaceuticals (ACAD), China Biologic Products (CBPO), Puma Biotechnology (PBYI), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Intrexon Corp (XON), SAGE Therapeutics (SAGE), Ultragenyx Pharmaceutical (RARE), Clovis Oncology (CLVS), Ligand Pharmaceuticals (LGND) and Agios Pharmaceuticals (AGIO).
Who owns bluebird bio stock?
bluebird bio's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (14.96%), Baillie Gifford & Co. (12.71%), Vanguard Group Inc. (7.85%), BlackRock Inc. (7.77%), State Street Corp (3.93%) and OppenheimerFunds Inc. (2.37%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mitchell H Finer, Nick Leschly and Philip D Gregory. View Institutional Ownership Trends for bluebird bio.
Who sold bluebird bio stock? Who is selling bluebird bio stock?
bluebird bio's stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Wells Fargo & Company MN, Emerald Advisers Inc. PA, JPMorgan Chase & Co., Emerald Mutual Fund Advisers Trust, Bank of America Corp DE, Columbus Circle Investors and Morgan Stanley. Company insiders that have sold bluebird bio stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore and Philip D Gregory. View Insider Buying and Selling for bluebird bio.
Who bought bluebird bio stock? Who is buying bluebird bio stock?
bluebird bio's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Vanguard Group Inc., State Street Corp, Baillie Gifford & Co., Pictet Asset Management Ltd. and FMR LLC. View Insider Buying and Selling for bluebird bio.
How do I buy bluebird bio stock?
Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of bluebird bio stock cost?
One share of bluebird bio stock can currently be purchased for approximately $79.80.
Earnings History for bluebird bio (NASDAQ:BLUE)Earnings History by Quarter for bluebird bio (NASDAQ:BLUE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/1/2017 | | | | | | | | |
| 5/3/2017 | Q1 2017 | ($1.76) | ($1.68) | $1.51 million | $6.83 million | View | N/A |  |
| 2/22/2017 | Q4 2016 | ($1.86) | ($1.88) | $1.76 million | $1.55 million | View | N/A | |
| 11/2/2016 | Q3 2016 | ($1.59) | ($2.07) | $1.82 million | $1.55 million | View | N/A | |
| 8/3/2016 | Q2 | ($1.44) | ($1.59) | $2.01 million | $1.55 million | View | N/A | |
| 5/4/2016 | Q1 | ($1.23) | ($1.52) | $4.50 million | $1.50 million | View | N/A | |
| 2/24/2016 | Q4 | ($1.11) | ($1.29) | $3.21 million | $1.47 million | View | N/A | |
| 11/4/2015 | Q3 | ($0.96) | ($1.18) | $5.63 million | $1.30 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.78) | ($1.57) | $8.60 million | $4.94 million | View | N/A | |
| 5/6/2015 | Q115 | ($0.68) | ($0.76) | $6.20 million | $6.30 million | View | N/A | |
| 2/25/2015 | Q414 | ($0.62) | ($0.66) | $6.20 million | $6.30 million | View | N/A | |
| 11/12/2014 | Q314 | ($0.52) | ($0.61) | $6.20 million | $6.40 million | View | N/A | |
| 8/12/2014 | Q214 | ($0.45) | ($0.06) | $6.15 million | $6.30 million | View | N/A | |
| 5/13/2014 | Q114 | ($0.32) | ($0.44) | $6.23 million | $6.30 million | View | N/A | |
| 3/5/2014 | | ($0.31) | ($0.34) | | | View | N/A | |
| 11/12/2013 | Q3 | ($0.25) | ($0.26) | $5.59 million | $6.39 million | View | N/A | |
| 8/8/2013 | Q213 | ($0.35) | ($2.13) | $4.85 million | $6.30 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for bluebird bio (NASDAQ:BLUE)2017 EPS Consensus Estimate: ($7.34)
2018 EPS Consensus Estimate: ($7.31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 5 | ($1.88) | ($1.79) | ($1.83) |
| Q2 2017 | 5 | ($1.89) | ($1.71) | ($1.78) |
| Q3 2017 | 5 | ($1.94) | ($1.73) | ($1.83) |
| Q4 2017 | 5 | ($2.03) | ($1.78) | ($1.89) |
| Q1 2018 | 1 | ($1.78) | ($1.78) | ($1.78) |
| Q2 2018 | 1 | ($1.81) | ($1.81) | ($1.81) |
| Q3 2018 | 1 | ($1.84) | ($1.84) | ($1.84) |
| Q4 2018 | 1 | ($1.88) | ($1.88) | ($1.88) |
(Data provided by Zacks Investment Research)
Dividend History for bluebird bio (NASDAQ:BLUE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for bluebird bio (NASDAQ:BLUE)Insider Ownership Percentage: 3.50%
Insider Trades by Quarter for bluebird bio (NASDAQ:BLUE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 4/27/2017 | Daniel Lynch | Director | Sell | 1,000 | $90.01 | $90,010.00 | |
| 4/25/2017 | Daniel Lynch | Director | Sell | 2,000 | $86.75 | $173,500.00 | |
| 4/10/2017 | Jeffrey T Walsh | Insider | Sell | 1,250 | $87.38 | $109,225.00 | |
| 4/3/2017 | David Davidson | Insider | Sell | 3,000 | $90.89 | $272,670.00 | |
| 3/27/2017 | Daniel Lynch | Director | Sell | 3,000 | $88.12 | $264,360.00 | |
| 3/16/2017 | Daniel Lynch | Director | Sell | 237 | $100.07 | $23,716.59 | |
| 3/16/2017 | Jason Cole | Insider | Sell | 4,930 | $100.07 | $493,345.10 | |
| 3/3/2017 | John Maraganore | Director | Sell | 13,839 | $85.02 | $1,176,591.78 | |
| 2/15/2017 | Daniel Lynch | Director | Sell | 150 | $80.22 | $12,033.00 | |
| 2/15/2017 | Jason Cole | Insider | Sell | 666 | $80.22 | $53,426.52 | |
| 2/14/2017 | Daniel Lynch | Director | Sell | 850 | $80.01 | $68,008.50 | |
| 2/14/2017 | Jason Cole | Insider | Sell | 3,772 | $80.01 | $301,797.72 | |
| 1/31/2017 | James Mandell | Director | Sell | 8,000 | $75.04 | $600,320.00 | |
| 1/27/2017 | Daniel Lynch | Director | Sell | 1,000 | $70.09 | $70,090.00 | |
| 1/27/2017 | David Davidson | Insider | Sell | 6,000 | $69.02 | $414,120.00 | |
| 1/5/2017 | Jason Cole | Insider | Sell | 549 | $67.10 | $36,837.90 | |
| 10/3/2016 | Eric Sullivan | Insider | Sell | 416 | $67.00 | $27,872.00 | |
| 9/13/2016 | Eric Sullivan | Insider | Sell | 416 | $59.00 | $24,544.00 | |
| 8/3/2016 | Eric Sullivan | Insider | Sell | 416 | $59.00 | $24,544.00 | |
| 7/27/2016 | Eric Sullivan | Insider | Sell | 2,912 | $55.01 | $160,189.12 | |
| 7/20/2016 | Eric Sullivan | Insider | Sell | 2,807 | $45.04 | $126,427.28 | |
| 7/15/2016 | David Davidson | Insider | Sell | 1,000 | $45.08 | $45,080.00 | |
| 6/16/2016 | Philip D Gregory | Insider | Sell | 2,931 | $39.52 | $115,833.12 | |
| 6/15/2016 | David Davidson | Insider | Sell | 1,000 | $40.11 | $40,110.00 | |
| 5/16/2016 | David Davidson | Insider | Sell | 1,000 | $38.73 | $38,730.00 | |
| 4/15/2016 | David Davidson | Insider | Sell | 1,000 | $49.63 | $49,630.00 | |
| 3/15/2016 | David Davidson | Insider | Sell | 1,000 | $46.13 | $46,130.00 | |
| 2/16/2016 | David Davidson | insider | Sell | 1,000 | $45.18 | $45,180.00 | |
| 1/15/2016 | David Davidson | insider | Sell | 1,000 | $44.39 | $44,390.00 | |
| 12/15/2015 | David Davidson | insider | Sell | 1,000 | $58.55 | $58,550.00 | |
| 12/8/2015 | Nick Leschly | CEO | Buy | 9,682 | $51.75 | $501,043.50 | |
| 11/16/2015 | David Davidson | insider | Sell | 2,000 | $70.99 | $141,980.00 | |
| 11/10/2015 | Jeffrey T. Walsh | COO | Sell | 11,000 | $74.60 | $820,600.00 | |
| 10/15/2015 | David Davidson | insider | Sell | 2,000 | $79.70 | $159,400.00 | |
| 10/12/2015 | Jeffrey T. Walsh | COO | Sell | 11,000 | $88.06 | $968,660.00 | |
| 10/9/2015 | Jason Cole | SVP | Sell | 5,000 | $86.91 | $434,550.00 | |
| 10/5/2015 | Daniel Lynch | Director | Sell | 3,000 | $100.41 | $301,230.00 | |
| 9/17/2015 | Daniel Lynch | Director | Sell | 1,500 | $140.06 | $210,090.00 | |
| 9/15/2015 | David Davidson | insider | Sell | 2,000 | $129.98 | $259,960.00 | |
| 9/10/2015 | Jeffrey T. Walsh | COO | Sell | 11,000 | $130.02 | $1,430,220.00 | |
| 9/9/2015 | Jason Cole | SVP | Sell | 2,000 | $136.56 | $273,120.00 | |
| 9/8/2015 | Daniel Lynch | Director | Sell | 7,000 | $132.75 | $929,250.00 | |
| 9/8/2015 | Nick Leschly | CEO | Sell | 125,000 | $135.24 | $16,905,000.00 | |
| 9/1/2015 | James Mandell | Director | Sell | 1,500 | $125.96 | $188,940.00 | |
| 7/20/2015 | Eric Sullivan | Insider | Sell | 1,126 | $163.36 | $183,943.36 | |
| 7/15/2015 | David Davidson | Insider | Sell | 2,000 | $165.96 | $331,920.00 | |
| 7/10/2015 | Jeffrey T Walsh | COO | Sell | 11,000 | $158.63 | $1,744,930.00 | |
| 7/9/2015 | Jason Cole | SVP | Sell | 5,000 | $158.19 | $790,950.00 | |
| 6/15/2015 | David Davidson | Insider | Sell | 2,000 | $183.34 | $366,680.00 | |
| 6/10/2015 | Jeffrey T Walsh | COO | Sell | 11,000 | $179.70 | $1,976,700.00 | |
| 6/1/2015 | Mitchell H Finer | Insider | Sell | 15,000 | $190.25 | $2,853,750.00 | |
| 4/20/2015 | Mitchell H Finer | Insider | Sell | 15,000 | $126.03 | $1,890,450.00 | |
| 4/15/2015 | David Davidson | Insider | Sell | 2,000 | $130.18 | $260,360.00 | |
| 4/10/2015 | Jeffrey T Walsh | COO | Sell | 21,000 | $126.21 | $2,650,410.00 | |
| 4/2/2015 | Eric Sullivan | Insider | Sell | 2,998 | $117.81 | $353,194.38 | |
| 3/10/2015 | Jeffrey T Walsh | COO | Sell | 10,500 | $110.06 | $1,155,630.00 | |
| 3/2/2015 | David Davidson | Insider | Sell | 4,000 | $94.84 | $379,360.00 | |
| 1/12/2015 | Jeffrey T Walsh | COO | Sell | 10,500 | $103.57 | $1,087,485.00 | |
| 1/2/2015 | David Davidson | Insider | Sell | 4,000 | $90.01 | $360,040.00 | |
| 12/19/2014 | John Maraganore | Director | Buy | 2,352 | $85.00 | $199,920.00 | |
| 12/10/2014 | Jeffrey T Walsh | COO | Sell | 43,500 | $78.06 | $3,395,610.00 | |
| 12/8/2014 | David Davidson | Insider | Sell | 15,000 | $46.10 | $691,500.00 | |
| 12/3/2014 | David Davidson | Insider | Sell | 3,000 | $41.65 | $124,950.00 | |
| 12/1/2014 | Mitchell H Finer | Insider | Sell | 18,000 | $39.70 | $714,600.00 | |
| 12/1/2014 | Nick Leschly | CEO | Sell | 2,417 | $39.70 | $95,954.90 | |
| 11/3/2014 | David Davidson | Insider | Sell | 3,000 | $41.68 | $125,040.00 | |
| 11/3/2014 | Nick Leschly | CEO | Sell | 25,000 | $41.68 | $1,042,000.00 | |
| 10/24/2014 | Nick Leschly | CEO | Sell | 33,900 | $40.22 | $1,363,458.00 | |
| 10/10/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $33.16 | $248,700.00 | |
| 10/9/2014 | Steven Gillis | Director | Sell | 115,000 | $35.25 | $4,053,750.00 | |
| 10/8/2014 | Mitchell H Finer | Insider | Sell | 34,518 | $33.52 | $1,157,043.36 | |
| 10/7/2014 | Steven Gillis | Director | Sell | 57,435 | $35.43 | $2,034,922.05 | |
| 10/2/2014 | Steven Gillis | Director | Sell | 91,165 | $35.28 | $3,216,301.20 | |
| 10/1/2014 | David Davidson | Insider | Sell | 3,000 | $34.55 | $103,650.00 | |
| 10/1/2014 | Nick Leschly | CEO | Sell | 8,000 | $34.55 | $276,400.00 | |
| 9/12/2014 | Robert I Tepper | Director | Sell | 125,000 | $36.54 | $4,567,500.00 | |
| 9/10/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $37.02 | $277,650.00 | |
| 9/2/2014 | David Davidson | Insider | Sell | 3,000 | $38.00 | $114,000.00 | |
| 9/2/2014 | Nick Leschly | CEO | Sell | 10,300 | $38.45 | $396,035.00 | |
| 8/11/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $34.26 | $256,950.00 | |
| 8/1/2014 | David Davidson | Insider | Sell | 3,000 | $33.62 | $100,860.00 | |
| 8/1/2014 | Nick Leschly | CEO | Sell | 8,000 | $33.62 | $268,960.00 | |
| 7/14/2014 | John Maraganore | Director | Buy | 2,941 | $34.00 | $99,994.00 | |
| 7/10/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $33.20 | $249,000.00 | |
| 7/3/2014 | Nick Leschly | CEO | Sell | 22,283 | $39.86 | $888,200.38 | |
| 7/1/2014 | David Davidson | Insider | Sell | 3,000 | $39.55 | $118,650.00 | |
| 6/20/2014 | Nick Leschly | CEO | Sell | 17,075 | $40.06 | $684,024.50 | |
| 6/16/2014 | Jeffrey T Walsh | COO | Sell | 1,500 | $39.86 | $59,790.00 | |
| 6/16/2014 | Mitchell H Finer | Insider | Sell | 10,000 | $39.84 | $398,400.00 | |
| 6/16/2014 | Nick Leschly | CEO | Sell | 42,925 | $40.02 | $1,717,858.50 | |
| 6/10/2014 | Jeffrey T Walsh | COO | Sell | 6,000 | $24.23 | $145,380.00 | |
| 6/2/2014 | Mitchell H Finer | Insider | Sell | 8,000 | $22.21 | $177,680.00 | |
| 6/2/2014 | Nick Leschly | CEO | Sell | 5,000 | $22.21 | $111,050.00 | |
| 5/14/2014 | Jeffrey Walsh | COO | Sell | 1,500 | $20.03 | $30,045.00 | |
| 5/12/2014 | Jeffrey Walsh | COO | Sell | 4,500 | $18.93 | $85,185.00 | |
| 5/1/2014 | David Davidson | Insider | Sell | 4,000 | $19.85 | $79,400.00 | |
| 5/1/2014 | Nick Leschly | CEO | Sell | 5,000 | $20.07 | $100,350.00 | |
| 4/10/2014 | Jeffrey Walsh | COO | Sell | 6,000 | $21.29 | $127,740.00 | |
| 1/22/2014 | Linda Bain | VP | Sell | 2,500 | $25.11 | $62,775.00 | |
| 1/17/2014 | Robert Tepper | Director | Sell | 307,000 | $22.43 | $6,886,010.00 | |
| 1/16/2014 | Mitchell Finer | Insider | Sell | 10,000 | $23.52 | $235,200.00 | |
| 1/14/2014 | Robert Tepper | Director | Sell | 340,000 | $21.90 | $7,446,000.00 | |
| 1/10/2014 | Jeffrey Walsh | COO | Sell | 6,000 | $21.98 | $131,880.00 | |
| 1/3/2014 | David Davidson | Insider | Sell | 15,000 | $20.88 | $313,200.00 | |
| 1/3/2014 | Linda Bain | VP | Sell | 5,000 | $20.89 | $104,450.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for bluebird bio (NASDAQ:BLUE)
Latest Headlines for bluebird bio (NASDAQ:BLUE)
| Source: |
|
| Date | Headline |
|---|
 | bluebird bio Announces Collaboration with Duke University's Robert J. Margolis, MD, Center for Health Policy on ... - Business Wire (press release)
www.businesswire.com - May 23 at 4:01 PM |
 | bluebird bio Announces Collaboration with Duke University’s Robert J. Margolis, MD, Center for Health Policy on Value-Based Payment Framework for Gene Therapy
finance.yahoo.com - May 23 at 12:26 PM |
| bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : May 23, 2017
finance.yahoo.com - May 23 at 12:26 PM |
| ETFs with exposure to bluebird bio, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 3:55 PM |
 | bluebird bio (BLUE) to Present New Data from LentiGlobin Clinical Studies at EHA - StreetInsider.com
www.streetinsider.com - May 18 at 11:40 AM |
| bluebird bio to Present Updated Clinical Results from Novel Anti ... - Business Wire (press release)
www.businesswire.com - May 18 at 11:40 AM |
| bluebird bio to Present New Data from LentiGlobinTM Clinical Studies at European Hematology Association (EHA) Annual Meeting
finance.yahoo.com - May 18 at 11:40 AM |
| bluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 17 at 9:01 PM |
 | bluebird bio Inc (BLUE) to Post FY2017 Earnings of ($6.78) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - May 15 at 8:50 AM |
| bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : May 12, 2017
finance.yahoo.com - May 12 at 4:30 PM |
| bluebird bio Inc (BLUE) Expected to Earn Q2 2017 Earnings of ($1.77) Per Share
www.americanbankingnews.com - May 12 at 10:40 AM |
 | Research Reports Coverage on Healthcare Stocks -- Radius Health, bluebird bio, Universal Health Services, and LifePoint Health
www.bizjournals.com - May 11 at 9:23 AM |
| bluebird bio Inc (BLUE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 9 at 9:06 AM |
| bluebird bio Inc (BLUE) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 8 at 11:26 PM |
| ETFs with exposure to bluebird bio, Inc. : May 8, 2017
finance.yahoo.com - May 8 at 8:53 PM |
| Morgan Stanley Reaffirms Equal Weight Rating for bluebird bio Inc (BLUE)
www.americanbankingnews.com - May 8 at 1:22 PM |
| Q2 2017 EPS Estimates for bluebird bio Inc (BLUE) Increased by Analyst
www.americanbankingnews.com - May 8 at 8:21 AM |
| SunTrust Banks Comments on bluebird bio Inc's Q2 2017 Earnings (BLUE)
www.americanbankingnews.com - May 8 at 8:21 AM |
| bluebird bio's (BLUE) "Hold" Rating Reiterated at Maxim Group
www.americanbankingnews.com - May 6 at 2:40 PM |
 | bluebird bio Updates, Investors Wait - Motley Fool
www.fool.com - May 5 at 8:59 PM |
| Analysts Issue Forecasts for bluebird bio Inc's Q1 2018 Earnings (BLUE)
www.americanbankingnews.com - May 5 at 5:24 PM |
| bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress - Business Wire (press release)
www.businesswire.com - May 5 at 3:58 PM |
| bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017
finance.yahoo.com - May 5 at 3:58 PM |
| bluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies - Business Wire (press release)
www.businesswire.com - May 4 at 9:06 PM |
| bluebird bio Inc (BLUE) Announces Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 4 at 4:43 PM |
| bluebird bio (BLUE) Earning Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - May 4 at 4:32 PM |
 | BRIEF-Bluebird bio Q1 total revenue $6.8 million
www.reuters.com - May 4 at 4:03 PM |
| bluebird bio (BLUE) , GlaxoSmithKline (GSK) Enters Lentiviral Vector Patent License Agreement - StreetInsider.com
www.streetinsider.com - May 3 at 9:01 PM |
| bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress - Yahoo Finance
finance.yahoo.com - May 3 at 9:01 PM |
| bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress
finance.yahoo.com - May 3 at 9:01 PM |
| Bluebird reports 1Q loss
finance.yahoo.com - May 3 at 9:01 PM |
| bluebird bio (BLUE) , GlaxoSmithKline (GSK) Enters Lentiviral Vector Patent License Agreement
www.streetinsider.com - May 3 at 10:34 AM |
| BRIEF-Bluebird Bio enters into patent license agreement with Glaxosmithkline for commercialization of Gene Therapies
www.reuters.com - May 2 at 5:53 PM |
| bluebird bio Inc (BLUE) Director Daniel Lynch Sells 1,000 Shares
www.americanbankingnews.com - May 1 at 10:18 PM |
| bluebird bio (BLUE) Earning Favorable Press Coverage, Report Shows
www.americanbankingnews.com - May 1 at 2:38 PM |
| bluebird bio Inc (BLUE) Rating Reiterated by BTIG Research
www.americanbankingnews.com - May 1 at 9:28 AM |
| bluebird bio Inc (BLUE) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 30 at 7:33 AM |
| Brokerages Anticipate bluebird bio Inc (BLUE) Will Post Quarterly Sales of $1.51 Million
www.americanbankingnews.com - April 29 at 10:17 AM |
| Better Buy: Ionis Pharmaceuticals, Inc. vs. bluebird bio - Motley Fool
www.fool.com - April 28 at 2:22 AM |
| bluebird bio Inc (BLUE) Director Daniel Lynch Sells 2,000 Shares
www.americanbankingnews.com - April 27 at 9:44 PM |
| bluebird bio to Present at Upcoming Investor Conferences - Yahoo Finance
finance.yahoo.com - April 27 at 4:19 PM |
| 3 Things You Didn't Know About bluebird bio, Inc. - Motley Fool
www.fool.com - April 27 at 4:19 PM |
| Better Buy: Ionis Pharmaceuticals, Inc. vs. bluebird bio
finance.yahoo.com - April 27 at 4:19 PM |
| Zacks: Analysts Anticipate bluebird bio Inc (BLUE) to Announce -$1.72 Earnings Per Share
www.americanbankingnews.com - April 27 at 8:48 AM |
| bluebird bio to Present at Upcoming Investor Conferences
finance.yahoo.com - April 26 at 6:09 PM |
| 3 Things You Didn't Know About bluebird bio, Inc.
finance.yahoo.com - April 26 at 1:09 PM |
| bluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : April 26, 2017
finance.yahoo.com - April 26 at 1:09 PM |
| bluebird bio (BLUE) Earning Positive Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 26 at 12:50 PM |
| bluebird bio Inc (BLUE) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 25 at 8:54 PM |
| bluebird bio (BLUE) Given Daily Media Sentiment Rating of 0.12
www.americanbankingnews.com - April 23 at 1:23 PM |
bluebird bio (BLUE) Chart for Thursday, May, 25, 2017
